Genus (GNS)

Sector:

Pharma and Biotech

Index:

FTSE 250

Trade now with BarclaysStockbrokers Trade now with Barclays Sponsored by Barclays Stockbrokers

2,608.00p
   
  • Change Today:
    -12.00p
  • 52 Week High: 2,992.00p
  • 52 Week Low: 2,098.00p
  • Currency: UK Pounds
  • Shares Issued: 65.05m
  • Volume: 492,097
  • Market Cap: 1,696.55m
  • RiskGrade: 174
  • Beta: 0.00
Select chart: 1 week | 1 month | 3 month | 6 month | 1 year
 

Current

1 week

Forecasts

Year Ending Revenue (m) Pre-tax (m) EPS P/E PEG EPS Grth. Div Yield
30-Jun-19 490.91 61.81 73.14p 35.7 n/a -4% 27.67p 1.2%
30-Jun-20 519.10 68.20 79.36p 32.9 3.9 +8% 30.30p 1.4%

Copyright © 2019 FactSet Research Systems Inc. All rights reserved.

Trends & Recommendations

  Current 1 week ago 1 month ago 3 months ago 6 months ago 1 year ago
Revenue (m)
30-Jun-2019 491 492 492 492 492 499
30-Jun-2020 519 n/a n/a n/a n/a n/a
 
Earnings
30-Jun-2019 73.14p 73.41p 73.41p 73.41p 73.70p 77.77p
30-Jun-2020 79.36p n/a n/a n/a n/a n/a
 
Dividend
30-Jun-2019 27.67p 27.72p 27.72p 27.72p 27.72p 28.06p
30-Jun-2020 30.30p n/a n/a n/a n/a n/a
 
Recommendations
Strong Buy 3 2 2 2 1 2
Buy 0 0 0 0 0 0
Neutral 2 2 2 2 3 3
Sell 0 0 0 0 0 0
Strong Sell 0 0 0 0 0 0
No. of Brokers 5 4 4 4 4 5
 
Average Rec 8.00 7.50 7.50 7.50 6.25 7.00

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

Note 3: Broker estimates sourced from FactSet Estimates +44 (0) 20 3009 7000. FactSet Estimates calculate consensus using only those estimates changed or actively validated within the last 75 days.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

IFRS Changes - Find Out More

Find out about IFRS and how this affects the financial infomation for all UK companies.

Genus Market Data

Currency UK Pounds
Share Price 2,608.00p
Change Today -12.00p
% Change -0.46 %
52 Week High 2,992.00p
52 Week Low 2,098.00p
Volume 492,097
Shares Issued 65.05m
Market Cap 1,696.55m
Beta 0.00
RiskGrade 174

Genus Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
95.62% below the market average95.62% below the market average95.62% below the market average95.62% below the market average95.62% below the market average
89.66% below the sector average89.66% below the sector average89.66% below the sector average89.66% below the sector average89.66% below the sector average
Price Trend
70.41% above the market average70.41% above the market average70.41% above the market average70.41% above the market average70.41% above the market average
57.38% above the sector average57.38% above the sector average57.38% above the sector average57.38% above the sector average57.38% above the sector average
Income
91.64% below the market average91.64% below the market average91.64% below the market average91.64% below the market average91.64% below the market average
69.23% below the sector average69.23% below the sector average69.23% below the sector average69.23% below the sector average69.23% below the sector average
Growth
71.18% below the market average71.18% below the market average71.18% below the market average71.18% below the market average71.18% below the market average
94.74% below the sector average94.74% below the sector average94.74% below the sector average94.74% below the sector average94.74% below the sector average

What The Brokers Say

Strong Buy 3
Buy 0
Neutral 2
Sell 0
Strong Sell 0
Total 5
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Genus Dividends

  Latest Previous
  Interim Final
Ex-Div 07-Mar-19 15-Nov-18
Paid 04-Apr-19 30-Nov-18
Amount 8.90p 17.90p

Trades for 14-Jun-2019

Time Volume / Share Price
16:35 9,672 @ 2,608.00p
16:29 16 @ 2,608.00p
16:26 92 @ 2,610.00p
16:26 40 @ 2,610.00p
16:26 47 @ 2,610.00p

Genus Key Personnel

Chair Robert (Bob) Lawson
CEO Karim Bitar

Top of Page